Kawano, S.; Fukushima, S.; Nishibata, K.; Gejima, R.; Miyano, S.W.
Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models. Cancers 2025, 17, 1084.
https://doi.org/10.3390/cancers17071084
AMA Style
Kawano S, Fukushima S, Nishibata K, Gejima R, Miyano SW.
Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models. Cancers. 2025; 17(7):1084.
https://doi.org/10.3390/cancers17071084
Chicago/Turabian Style
Kawano, Satoshi, Sayo Fukushima, Kyoko Nishibata, Ryu Gejima, and Saori Watanabe Miyano.
2025. "Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models" Cancers 17, no. 7: 1084.
https://doi.org/10.3390/cancers17071084
APA Style
Kawano, S., Fukushima, S., Nishibata, K., Gejima, R., & Miyano, S. W.
(2025). Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models. Cancers, 17(7), 1084.
https://doi.org/10.3390/cancers17071084